TRADU
8.5.2024 09:01:35 CEST | Business Wire | Press release
Tradu, the powerful multi-asset trading platform, has launched a new crypto exchange with low, transparent fees tailored for active traders and investors seeking a trustworthy and secure platform for their crypto assets. From today, crypto traders can securely invest in over 40 coins including Bitcoin and Ethereum via Tradu’s multi-asset trading platform. Tradu is part of Stratos Group International, LLC (“Stratos”), a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF).
Tradu is taking a fresh approach to crypto, offering a simple and transparent cost structure that saves investors up to 95% of the fees that can be charged in crypto trading. The platform displays commissions and real-time spreads before orders are placed, giving traders full transparency on all transaction costs. Tradu charges just 0.1% commission with instant rebates of 0.02% and 0.05% for larger trade sizes. The commission for a 1 BTC trade (at a price of $60,000) is just $30 at Tradu versus as much as $600 at other exchanges.*
Tradu clients can also choose to trade on a commission-free profile opting to instead add the fee to the spread. Clients can simply click to change between the Zero Commission and the Raw Spreads profile options in the platform. Clients have the flexibility to choose the profile that best suits their trading style.
Other key features include:
Uniform trading fees: Tradu maintains equal fees for maker and taker transactions, promoting fairness, simplicity and transparency in trading.
Free crypto deposits and easy withdrawals: Crypto deposits are free with Tradu while withdrawals are easy and fees are simple and clear.
Comprehensive support: Access customer support through various channels, including email, chat, and phone, ensuring prompt assistance for user queries.
Brendan Callan, CEO of Tradu, commented: “At Tradu, we are real supporters of crypto. It’s a huge market with significant investor interest and as a true multi-asset trading platform, it’s important for us to offer our clients access to both traditional assets and new digital assets. We are bringing institutional-grade pricing and infrastructure to the retail crypto market, providing traders with upfront costs and tight, transparent spreads enabling active traders and investors to maximise their returns. Tradu is focused on creating stable, secure and frictionless cryptocurrency trading through technology, delivering a better, safer and lower cost service. Clients can reach out to our support team for detailed instructions on how to transfer their crypto portfolio over to Tradu.”
In addition to cryptocurrencies, Tradu users can also access over 10,000 trading products across equities, forex and CFDs on commodities, stocks, treasuries and indices all from one powerful portal that can be accessed via a user-friendly mobile app and web platforms.
Visit crypto.tradu.com to sign up and gain access to a wide range of assets**.
Notes to editors
* Costs calculated based on buying one Bitcoin at a price of $60,000. Tradu cost includes a 0.05% rebate based on order size. Comparative pricing based on a standard account type and information from broker websites as of 1st May 2024. It does not reflect the whole market. Actual fees may vary due to factors like account type, rebates, volume, and market conditions.
**Products vary depending on location, visit tradu.com to check which products are available in your region.
About Tradu
Tradu is headquartered in London with offices around the world. The global Tradu team speaks more than two dozen languages and prides itself on its responsive and helpful client support.
Stratos also operates FXCM, an FX and CFD platform founded in 2001. Stratos will continue to offer FXCM services alongside Tradu’s multi-asset platform.
Stratos subsidiaries are authorised and regulated in the UK, Europe, Australia and South Africa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508810010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom